Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's ...

Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...

Viking Therapeutics (VKTX) shares are taking a dive in Monday's session despite on rising manufacturing concerns and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Truist Financial analyst Joon Lee assigned a Buy rating to the stock today. The company’s shares closed last Friday at $72.88. Lee covers ...

On Oct. 24, VKTX surged by 21% after announcing better-than-expected third-quarter results, including positive updates on its ...

Viking Therapeutics (VKTX) surges on promising obesity drug results. Explore key price levels and analyst insights in this detailed analysis.

Below is Validea's guru fundamental report for VIKING THERAPEUTICS INC (VKTX). Of the 22 guru strategies we follow, VKTX rates highest using our P/B Growth Investor model based on the published ...

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.

Investing.com - Viking Therapeutics Inc (NASDAQ: VKTX) reported fourth quarter EPS of $-0.260, $0.03 worse than the analyst estimate of $-0.230. Revenue for the quarter came in at ...